Another ligand of FcγRIIb, fibrinogen-like protein 2 (FGL2), was found to be increased in NAFLD patients demonstrating severe forms of NAFLD, suggesting a decrease in FcγRIIb expression (Colak et al., 2011). Here, FGL2 is linked to metabolic dysfunction-associated steatotic liver disease.